Choi, Stephen
June 2004
CMAJ: Canadian Medical Association Journal;6/8/2004, Vol. 170 Issue 12, p1787
Academic Journal
Discusses research being done on gefitinib, a drug originally designed to inhibit the epidermal growth factor receptor (EGFR) kinase enzyme. Reference to a study by Paez et al, which appeared in the April 29, 2004 issue of "Science" journal; Differences about the EGFR of Japanese and European patients.


Related Articles

  • New Developments in Systemic Therapy for Hepatocellular Carcinoma. Dourakis, Spyros P. // Current Cancer Therapy Reviews;2008, Vol. 4 Issue 3, p219 

    Unresectable or metastatic hepatocellular carcinoma (HCC) carries a poor prognosis. Hepatic reserve often dictates the therapeutic options. There have been multitudes of negative systemic therapy trials for advanced HCC unsuitable for surgical and locoregional therapy up until now. Hormonal...

  • Research highlights 2007.  // Nature;12/14/2007, Vol. 450 Issue 7173, p1130 

    The article highlights several scientific research papers published in 2007, which were selected by "Nature" editors. One of these research papers discusses the successful preparation of stem-like cells, which can develop into almost any cell types of the body, from adult mouse skin cells. The...

  • Anything but 'TDM' in San Antonio.  // BioWorld Today;12/15/2009, Vol. 20 Issue 240, p5 

    The article reports on the positive interim results of the Phase I trial of ARRY-380, a small molecule HER2 (Human Epidermal Growth Factor Receptor 2) (ErbB2) inhibitor, in advanced cancer patients. The Phase I trial of the drug from Array BioPharma Inc. has revealed that the drug at doses...

  • Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. Ying-Chun Shen; Chiun Hsu; Ann-Lii Cheng // Journal of Gastroenterology;Aug2010, Vol. 45 Issue 8, p794 

    Sorafenib, a multikinase inhibitor targeting vascular endothelial growth factor (VEGF)-mediated angiogenesis, is the first drug found to prolong survival of patients with advanced hepatocellular carcinoma (HCC). This advance has shifted the paradigm of systemic treatment for HCC toward molecular...

  • Report from the European Society for Medical Oncology Congress. Zer, Alona // Oncology Exchange;Nov2014, Vol. 13 Issue 4, p32 

    The article reports on the findings of a study which examines the safety and effectiveness of gefitinib in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) patients with acquired resistance to first-line gefitinib. It confirms that the continuation of...

  • Neuroendocrine tumors and CUP.  // Annals of Oncology;Sep2012 Supplement 9, Vol. 23 Issue suppl_9, pix376 

    No abstract available.

  • Anything but 'TDM' in San Antonio.  // BioWorld Today;12/15/2009, Vol. 20 Issue 240, p6 

    The article reports on preliminary results from the two-part trial being conducted by Pfizer Inc. to determine the safety and efficacy of oral pan-ErbB inhibitor neratinib in combination with weekly paclitaxel in patients with solid tumors and patients with Human Epidermal growth factor Receptor...

  • Effects of Icotinib on Advanced Non-Small Cell Lung Cancer with Different EGFR Phenotypes. Pan, Huiyun; Liu, Rong; Li, Shengjie; Fang, Hui; Wang, Ziwei; Huang, Sheng; Zhou, Jianying // Cell Biochemistry & Biophysics;Sep2014, Vol. 70 Issue 1, p553 

    Icotinib is the first oral epidermal growth factor receptor (EGFR) tyrosine kinase receptor inhibitor, which has been proven to exert significant inhibitory effects on non-small cell lung cancer in vitro. Clinical evidence has showed that the efficacy of Icotinib on retreating advanced non-small...

  • Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics. Motoshima, Kohei; Nakamura, Yoichi; Sano, Kazumi; Ikegami, Yoji; Ikeda, Takaya; Mizoguchi, Kosuke; Takemoto, Shinnosuke; Fukuda, Minoru; Nagashima, Seiji; Iida, Tetsuya; Tsukamoto, Kazuhiro; Kohno, Shigeru // Cancer Chemotherapy & Pharmacology;Dec2013, Vol. 72 Issue 6, p1299 

    Background: We conducted a phase II trial of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations and evaluated the relationship between plasma concentration and efficacy of erlotinib. Methods: Patients who were...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics